Leveraging microenvironmental synthetic lethalities to treat cancer
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Treatment resistance leads to cancer patient mortality. Therapeutic approaches that employ synthetic lethality to target mutational vulnerabilities in key tumor cell signaling pathways have proven effective in overcoming therapeutic resistance in some cancers. Yet, tumors are organs composed of malignant cells residing within a cellular and noncellular stroma. Tumor evolution and resistance to anticancer treatment are mediated through a dynamic and reciprocal dialogue with the tumor microenvironment (TME). Accordingly, expanding tumor cell synthetic lethality to encompass contextual synthetic lethality has the potential to eradicate tumors by targeting critical TME circuits that promote tumor progression and therapeutic resistance. In this Review, we summarize current knowledge about the TME and discuss its role in treatment. We outline the concept of tumor cell-specific synthetic lethality and describe therapeutic approaches to expand this paradigm to leverage TME synthetic lethality to improve cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The blood and lymphatic ECs, complex collagen fibers and glycoproteins form the ECM, while the cancer‐associated fibroblasts (CAFs) and mesenchymal stem cells further assist in ECM remodeling and even chemoresistance [13, 14].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Yet many tumors are abnormally and poorly vascularized, which causes nutrient-poor and hypoxic regions within tumors (101).”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Overview of the tumor microenvironment and drug resistance Tumors are composed of a population of cancer cells that are genetically, phenotypically, and spatially heterogeneous, and this heterogeneity correlates with drug resistance (11, 12).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“PARP, BRCA1, and BRCA2 contribute to DNA repair, making cancer cells carrying BRCA mutations more sensitive to PARP inhibitors (97, 98).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“The blood and lymphatic ECs, complex collagen fibers and glycoproteins form the ECM, while the cancer-associated fibroblasts (CAFs) and mesenchymal stem cells further assist in ECM remodeling and even chemoresistance [13, 14].”
BackgroundChen, S., Morine, Y., Tokuda, K., Yamada, S., Saito, Y., Nishi, M., Ikemoto, T., & Shimada, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5239 · Cited by 168
Mechanical state transitions in the regulation of tissue form and function
Mao, Y., & Wickström, S. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00719-x · Cited by 162
Qian, J., LeSavage, B. L., Hubka, K. M., Ma, C., Natarajan, S., Eggold, J. T., Xiao, Y., Fuh, K. C., Krishnan, V., Enejder, A. M. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146186 · Cited by 138
“Discussion Accumulating evidence suggests that the tumor microenvironment plays an important role in shaping tumor heterogeneity and drug resistance (65).”
BackgroundPancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis
Saab, J. J. A., Dzierozynski, L. N., Jonker, P. B., AminiTabrizi, R., Shah, H., Menjivar, R. E., Scott, A. J., Nwosu, Z. C., Zhu, Z., Chen, R. N., et al. (2023) · eLife · doi:10.7554/elife.81289 · Cited by 88
“, 2007), we anticipate ensuring proper nutrient availability will be critical in the development of more physiologically relevant ex vivo cancer models, which will expand our ability to target cancer by enabling exploitation of microenvironmentally driven therapeutic targets (Metcalf et al., 2021; Sela et al., 2022).”
BackgroundNew Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Previtali, V., Bagnolini, G., Ciamarone, A., Ferrandi, G., Rinaldi, F., Myers, S. H., Roberti, M., & Cavalli, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00113 · Cited by 87
“…genetic interactions, thereby prompting the recognition of condition-dependent forms of SL, often termed as “contextual” or “conditional” SL. 12,13 Herein, we build upon our previously published Perspective in the Journal of Medicinal Chemistry 14 to describe the latest trends in drug…”
BackgroundCan’t handle the stress? Mechanobiology and disease
Zuela-Sopilniak, N., & Lammerding, J. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.010 · Cited by 73
Punovuori, K., Bertillot, F., Miroshnikova, Y. A., Binner, M., Myllymäki, S.-M., Follain, G., Kruse, K., Routila, J., Huusko, T., Pellinen, T. S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.046 · Cited by 73
Fibroblasts as Turned Agents in Cancer Progression
Wieder, R. (2023) · Cancers · doi:10.3390/cancers15072014 · Cited by 57
Identifying metabolic limitations in the tumor microenvironment
Cognet, G., & Muir, A. (2024) · Science Advances · doi:10.1126/sciadv.adq7305 · Cited by 72
“These metabolic liabilities are termed microenvironmental or contextual synthetic lethal targets ( 7 , 8 ).”
BackgroundDrug repositioning for cancer in the era of AI, big omics, and real-world data
Wieder, R., & Adam, N. R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103730 · Cited by 42
Matarrese, P., Mattia, G., Pagano, M., Pontecorvi, G., Ortona, E., Malorni, W., & Carè, A. (2021) · Cancers · doi:10.3390/cancers13133287 · Cited by 34
“, those mediated by cell adhesion features, TME can exert a critical function by co-stimulating (or co-inhibiting) the clonal selection, thus leading to a metastatic or drug-resistant phenotype as well as contributing to cancer-associated angiogenesis [2].”
BackgroundWang, L., Jiang, S., Yuan, Y., Duan, J., Mao, N., Hui, Z., Bai, R., Xie, T., & Ye, X. (2022) · Molecules · doi:10.3390/molecules27082491 · Cited by 29
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
Ge, M., Luo, J., Wu, Y., Shen, G., & Kuang, X. (2024) · MedComm – Oncology · doi:10.1002/mog2.70 · Cited by 39
The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer
Zheng, A., Wei, Y., Zhao, Y., Zhang, T., & Ma, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1013506 · Cited by 27
Iessi, E., Vona, R., Cittadini, C., & Matarrese, P. (2021) · Biomedicines · doi:10.3390/biomedicines9121942 · Cited by 30
“The interactions between cellular and non-cellular components of the TME, through the above mediators, activate several signaling pathways, which can act by favoring or disadvantaging tumor progression, invasion, and drug resistance, as well as contributing to cancer-associated angiogenesis [78,79].”
BackgroundChallenges and Opportunities Modeling the Dynamic Tumor Matrisome
Peyton, S. R., Platt, M. O., & Cukierman, E. (2023) · BME Frontiers · doi:10.34133/bmef.0006 · Cited by 25
What’s on the menu?: metabolic constraints in the pancreatic tumor microenvironment
Sheehan, C. S., & Muir, A. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191940 · Cited by 20
Luong, T., & Cukierman, E. (2022) · BMC Cancer · doi:10.1186/s12885-022-10330-y · Cited by 16
“elimination has been demonstrated to be advantageous to PDAC progression and deleterious to patients [7–9], the field has placed significant efforts on identifying potential stroma-normalizing drugs that can harness the natural tumor-suppressive function of fibroblastic cells [6, 12, 13].”
BackgroundBehrooz, A. B., & Shojaei, S. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167332 · Cited by 17
Emerging trends and converging evidence in tumor evolution: A comprehensive review
Jin, C., Li, W., Liu, B., Cao, L.-Q., Stefan, S. M., Yuan, L., Yu, X., Shi, L., & Yu, H. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101380 · Cited by 13
Malhan, D., Hesse, J., Nelson, N., Stankov, K., Nguyen, J., Aboumanify, O., Garmshausen, J., Rogmans, G., Czogalla, B., Gerber, J., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105764 · Cited by 11
“86,87 However, the associated toxicity remains a signi fi cant challenge.”
Islam, S. S., Almohanna, F., Yousef, I. M., Al-Badawi, I. A., & Aboussekhra, A. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06512-0 · Cited by 10
MCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors
Li, X., Han, Y., Jin, Z., Jiang, K., Xue, K., Wang, J., Qian, Y., Xiang, Q., Zhu, S., Yan, R., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240959 · Cited by 8
“Because chemotherapy has been shown to act partly by stimulating anti-tumor immunity via cell damage (Gotwals et al., 2017; Metcalf et al., 2021), we reasoned that immune sensitization by MCRS1 could amplify such effects to enhance treatment efficacy further.”
Xiong, Q., Jin, J., Lin, J., Zhang, B., Jiang, Y., Sun, Z., Zhang, L., Wu, Y., Zhao, G., Qin, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101290 · Cited by 8
Wu, Z., & Ju, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888276 · Cited by 9
Potential promising of synthetic lethality in cancer research and treatment
Fath, M. K., Najafiyan, B., Morovatshoar, R., Khorsandi, M., Dashtizadeh, A., Kiani, A., Farzam, F., Kazemi, K. S., & Nabi‐Afjadi, M. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03444-6 · Cited by 10
“Inhibiting gene B in normal cells, where gene A remains intact, would not result in SL or cell death (Metcalf et al. 2021; O'Neil et al. 2017a, b; Shaheen et al. 2011) (Fig.”
Have plastic culture models prevented the discovery of effective cancer therapeutics?
Tharp, K. M. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17387 · Cited by 3
“…cells cultured in these soft or stiff microenvironments show significant differences in sensitivity to chemotherapeutics (Drain et al., 2021; Metcalf et al., 2021; Tharp et al., 2021), which establishes a concerning question for anti-cancer drug discovery: Do stiff plastic surfaces bias…”
Testa, C., Pidò, S., Jacchetti, E., Raimondi, M. T., Ceri, S., & Pinoli, P. (2023) · International Conference on Bioinformatics and Biomedical Technology (ICBBT) · doi:10.1145/3608164.3608171 · Cited by 3
Context-dependent synthetic lethality — an emerging precision therapeutic approach
Chang, L., Shaw, K. L., Vázquez, F., & Sellers, W. R. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00929-9 · Cited by 8
“Indeed, extrinsic factors such as hypoxia and nutrient availability have been shown to reshape DNA repair and metabolic synthetic lethalities 126,129,267 , highlighting the value of model systems that capture these microenvironmental influences 268,269 .”
Materials-driven approaches to understand extrinsic drug resistance in cancer
Pritchard, J. R., Lee, M. J., & Peyton, S. R. (2022) · Soft Matter · doi:10.1039/d2sm00071g · Cited by 1
Oncometabolite signatures from tumor-stroma crosstalk as potential non-invasive biomarkers
Parascandolo, A., Magnifico, M. C., Vita, E., Hematti, P., Distante, C., Corcione, F., Varelli, M., Cutruzzolà, F., Macone, A., & Laukkanen, M. O. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03172-1 · Cited by 1
Jonker, P. B., Sadullozoda, M., Cognet, G., Saab, J. J. A., Sokol, K. H., Wu, V. X., Kumari, D., Sheehan, C. S., Özgürses, M. E., Agovino, D., et al. (2025) · eLife · doi:10.7554/elife.106492.1 · Cited by 1
Jonker, P. B., Sadullozoda, M., Cognet, G., Saab, J. J. A., Sokol, K. H., Wu, V. X., Kumari, D., Sheehan, C. S., Özgürses, M. E., Agovino, D., et al. (2026) · eLife · doi:10.7554/elife.106492 · Cited by 3
“Since healthy tissues do not face these constraints or require similar adaptive mechanisms, such adaptations could be novel anti-neoplastic drug targets that may be targetable with a wide therapeutic index ( Cognet and Muir, 2024 ; Metcalf et al., 2021 ; Chan et al., 2010 ; Kaelin, 2005 ).”
Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating TGFβ inhibitionPreprint
Luong, T., & Cukierman, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.25.482033
“Since quiescent/normal fibroblasts are naturally tumor-suppressive [10] and because CAF elimination has been demonstrated to be advantageous to PDAC progression and deleterious to patients [7-9], the field has placed significant efforts on identifying potential stroma-normalizing drugs [6, 12, 13].”
BackgroundJonker, P. B., Sadullozoda, M., Cognet, G., Saab, J. J. A., Sokol, K. H., Wu, V. X., Kumari, D., Sheehan, C. S., Özgürses, M. E., Agovino, D., et al. (2026) · eLife · doi:10.7554/elife.106492.3 · Cited by 1
Liang, T., Luo, L., Du, Y., Yang, X., Xu, X., Guo, H., He, Z., Yang, G., & Guo, L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102057
Synthetic lethality by poly (ADP-ribose) polymerase inhibitors
Perween, S., Patidar, V., Kumar, S., Dahiya, S., & Singh, R. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44041-0.00015-5
CRISPR approaches: Modeling tumor-stroma interactions and their role in cancer progression
Raninga, B., & Gupta, P. S. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102569
Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation
Camps-Fajol, C., Minguillón, J., & Surrallés, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02954-4 · Cited by 3
“6,7 Cancer is considered a disease of the genome.”
Niches in cancer: from primary tumors to metastatic disease
Chao, Z., Wang, X., Wang, Z., Wu, K., & Li, L. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01858-8
“Such overlap helps explain why similar malignant phenotypes can arise in different tissues and at different stages of disease [27, 28].”
Metadata
- Authors
- Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Weaver, Valerie M.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-03-15
- Volume
- 131
- Issue
- 6
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7954586
- OpenAlex
- W3136876771
- Cited by
- 42
- References
- 145
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 10 · 2023: 5 · 2022: 8 · 2021: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R35CA242447, R01CA227942)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- synthetic lethality, tumor microenvironment, treatment resistance, cancer therapy, tumor stroma, tumor evolution
- MeSH terms
- Synthetic Lethal Mutations, Animals, Female, Humans, Immunotherapy, Male, Neoplasms, Signal Transduction, Disease Progression, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.